The objective of this study is to address the anti-inflammatory effect of tocotrienol supplementation in subjects with moderately elevated inflammation. It is hypothesized that 6 months supplementation of tocotrienols will reduce inflammatory markers of subjects.
A double-blind, randomized, placebo-controlled, parallel study comparing the effect of tocotrienols vs. placebo will be conducted in subjects with moderately elevated inflammation. Subjects will be supplemented with Tocovid Suprabio 200 mg twice daily or placebo for 6 months. Fasting blood samples will be collected at baseline, 3 months, 6 months. A post-study fasting blood sample will be collected at 9 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
180
1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: 200 mg Tocotrienol-rich fraction
1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: Palm olein
Malaysian Palm Oil Board
Kajang, Selangor, Malaysia
RECRUITINGInflammation
Change in high-sensitivity c-reactive protein (hs-CRP)
Time frame: 0, 3, 6, 9 months
Inflammatory markers
Changes in IL-6, IL-1alpha, IL-1beta, TNF-alpha, E-selectin, ICAM-1, VCAM-1
Time frame: 0, 3, 6, 9 months
Thrombotic markers
Changes in PAI-1, D-dimer
Time frame: 0, 3, 6, 9 months
Lipid profile
Changes in TC, LDL, HDL, ApoA1, ApoB
Time frame: 0, 3, 6, 9 months
Glucose homeostasis
Changes in Glucose, insulin, c-peptide
Time frame: 0, 3, 6, 9 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.